Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Santen Bags Global Rights to Aerie’s Glaucoma Meds, Except US, in Expanded Pact
Santen Pharmaceutical said on December 7 that it has signed a deal to extend the reach of its exclusive license for two glaucoma drugs of US ophthalmology specialist Aerie Pharmaceuticals, grabbing the rights to develop and commercialize them worldwide, excluding…
To read the full story
Related Article
- Santen Files Glaucoma Drug Rhopressa in Japan
July 31, 2025
- Santen’s Glaucoma Med Rhopressa Hits Shelves in South Korea
November 5, 2024
- Santen Gets Asian Rights to Aerie’s Glaucoma Meds
October 29, 2020
BUSINESS
- Japan Approves Fuji’s New Stelara, Simponi Biosimilar Formulations
September 17, 2026
- Maruishi Clinches Japan Rights to Kringle’s Vocal Fold Scar Drug
September 17, 2026
- Nobelpharma, Fuso to Co-Promote Hypozincemia Drug Zintus
September 17, 2026
- Sanofi Japan Targets AI Fluency across Workforce by End-2027
September 16, 2026
- Mounjaro Label Updated with PIII CV Data Showing Noninferiority
September 16, 2026
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…